Merck expands in Asia and proposes to acquire Australia’s Viralytics

7 March 2018 - 0 Submitted by Charlotte Niemiec

Leading science and technology company Merck (known as MilliporeSigma in the US) has announced agreements in China, India and South Korea that will see the company invest €40 million in the region.

The company has signed an agreement with Incheon Free Economic Zone (IFEZ) to build an integrated cell culture facility in Songdo, Incheon. Located on 10,141m² of land, the new centre will include cell culture media facilities and a logistics infrastructure. Construction is expected to begin in May 2018 and to be completed by mid-2019.

In India, Merck will invest €16.6 million in a new manufacturing and distribution centre for the Life Science business. The new centre, located in the Patalganga industrial area, near Mumbai, is expected to be completed in 2019. Occupying 10 acres (4 ha), the site spans more than 12,000m². The facility will house a solids down-filling operation, giving the Life Science business a competitive advantage through improved fill rates and increased capacity.

China: biotech powerhouse

In China, Merck has announced an additional investment to accelerate Mobius single-use manufacturing in Wuxi, China. The investment follows a year after Merck announced its €80 million Life Science investment in Nantong, China in November 2016. China is fast becoming a biotech powerhouse with a promising bio similar industry. Single-use capacity is critical for biosimilar development and manufacturing because of their flexibility and efficiency. The site expansion is expected to be completed in the second half of 2018.

Viralytics proposal

Additionally, Merck has made proposals to purchase Viralytics, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers. The proposed acquisition values the total issued shares in Viralytics at approximately A$502 million (US$394 million).

On completion of the transaction, Viralytics will become a wholly-owned subsidiary of Merck. Merck will gain full rights to Cavatak, Viralytic’s investigational oncolytic immunotherapy, which is currently being evaluated in multiple phase one and two clinical trials.

Seqens opens ‘I&D’ centre

Jun 18, 2019/0

Seqens has officially opened its main innovation and development (I&D) centre called Seqens’Lab at Porcheville, near Paris, with a ribbon-cutting ceremony performed by Agnès Pannier-Runacher, secretary of state to the Minister of Economy & Finance.

Lonza invests more in HPAPIs

Jun 18, 2019/0

Lonza is to expand high potency API (HPAPI) capacity at its main site at Visp, Switzerland, in response to demand.

What does digitization mean for the chemicals industry?

May 22, 2019/0

In partnership with consulting firm EY, Speciality Chemicals Magazine is launching a survey of the state of digtalization in the chemicals industry. And we need your help! It is entirely confidential, based on mainly multiple choice questions and should only take 5 minutes to complete.

Thermo Fisher buys GSK Irish site

May 20, 2019/0

Thermo Fisher Scientific, owner of Patheon, has agreed to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline (GSK) for about €90 million. The deal should be completed by the end of 2019, subject to regulatory approvals and other customary closing condition.

Queen's Awards for four UK-based chemical operations

Apr 25, 2019/0

Four companies with operations in the UK have been honoured in the latest round of the Queen’s Award for Enterprise. Diamond Dispersions, Sterling Pharma Solutions and Leverton Clarke all won in the International Trade category, Biocatalysts in the Innovation category.

Ten die in Chinese pharma plant accident

Apr 25, 2019/0

Ten workers were killed in an accident at a pharmaceutical intermediates and APIs plant in China’s Shandong province on 15 April, it has emerged. This was the second fatal industrial accident at a chemicals-related plant in China within the space of a month.